Navigation Links
Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
Date:8/3/2010

SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced the online publication of results from its COR-BMOD trial of Contrave® (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification (BMOD) plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients. The addition of Contrave to BMOD delivered significant incremental weight loss and improvements in measures of cardiometabolic risk.  Results showed that patients taking Contrave lost 9.3% of their body weight compared to 5.1% for patients on placebo (p< 0.001), on an intent-to-treat basis.  For those who completed 56 weeks of treatment, patients taking Contrave plus BMOD lost 11.5% of their body weight compared to 7.3% for those taking placebo (p<0.001).

Behavior modification, including diet and exercise, has long been considered the standard of care in managing obesity.  The benefit of adding specific pharmacotherapies to a rigorous BMOD program has not been extensively evaluated.  COR-BMOD was designed to test this hypothesis by evaluating Contrave in a setting conducive to maximum weight loss in which patients used the medication as part of a broader weight-loss effort.  Participants in both groups received diet and exercise counseling during 28 small group sessions with one or two professionals, each lasting 90 minutes, over the course of the year-long trial.

"There is no magic bullet for the treatment of obesity.  For some patients, effective and sustainable treatment is going to require a multi-modal approa
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Hepatitis C Therapeutics Market - Taiwan
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Abviva Announces Notice of Canadian Patent for Technology Used in Breast Cancer Diagnostics and Therapeutics
9. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
10. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
11. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, ... devoted to bringing new products to market, has ... called TetraStem. TetraStem is a topical liquid tetracycline-based ... system that can convert oral medication active ingredients ... as a first aid antibiotic to help prevent ...
(Date:10/30/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Wednesday, November 5, 2014 ... management will hold a conference call at 7:30 a.m. ... 8:30 p.m., Beijing Time on November 6, 2014, to ...
(Date:10/30/2014)... MADRID , October 30, 2014 ... hidrolizada con probiótico LGG contribuye a adquirir tolerancia ... La alergia a la proteína de la leche ... lactantes y primera infancia. Hasta ahora, la APLV ... dieta. Recientemente, se ha demostrado que es posible ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... of data from more than 12,000 people with cystic fibrosis ... infection in the Cystic Fibrosis Foundation,s Patient Registry shows that ... associated with a 21% reduction in mortality in the following ... North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, sponsored ...
... Bionovo, Inc. (Nasdaq: BNVI ) today announced ... discussing new classes of estrogen receptor modulating drugs with ... in the most recent edition of Current Opinion ... Specific Target Genes and Biological Responses by Estrogen Receptor ...
Cached Medicine Technology:Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 2Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 3Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 4Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection 5Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 2Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 3Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions 4
(Date:10/30/2014)... have to be at least 2 years old to ... no official U.S. guidance exists other than the general ... breastfeed for at least the first six months. , ... That,s the question that motivated researchers at the University ... study the eating patterns of American infants at 6 ...
(Date:10/30/2014)... 2014 Nutrition Leaders, a popular online ... aids, and more, is currently hosting a sweepstakes on ... underway, is open to U.S. residents age 18 and ... 2014. One lucky winner will then be selected at ... gift card to NutritionLeaders.com. , Nutrition Leaders’ managing director ...
(Date:10/30/2014)... Burlington, NC (PRWEB) October 30, 2014 ... life, commercial, and health insurance plans for North Carolina ... its satellite office in Burlington’s Holly Hill Mall. The ... 15, with agents already helping customers through all facets ... policy purchase. , Allred Insurance spokesman Scott Allred couldn’t ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer in prediabetes ... a supply of sugardown®, a chewable dietary supplement that ... spikes. Learning how to control blood sugar levels and ... diabetes prevention plan. , Shoppers who spend $50 or ... sugardown. The offer expires November 30. , Full-size ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: